প্রকাশ: 18/01/2022
A fourth shot of Covid-19 vaccine boosts antibodies to even
higher levels than the third jab but it is not enough to prevent Omicron
infections, according to a preliminary study in Israel.
Israel's Sheba Medical Center has given second booster shots
in a trial among its staff and is studying the effect of the Pfizer booster in
154 people after two weeks and the Moderna booster in 120 people after one
week, said Gili Regev-Yochay, director of the Infectious Diseases Unit.
These were compared to a control group that did not receive
the fourth shot. Those in the Moderna group had previously received three shots
of Pfizer's vaccine, the hospital said.
The vaccines led to an increase in the number of antibodies
"even a little bit higher than what we had after the third dose",
said Regev-Yochay.
"Yet, this is probably not enough for the
Omicron," she told reporters. "We know by now that the level of
antibodies needed to protect and not to get infected from Omicron is probably
too high for the vaccine, even if it's a good vaccine."
The findings, which the hospital said were the first of its
kind in the world, were preliminary and not yet published.
Israel was the fastest country to roll out initial
vaccinations against Covid-19 a year ago and last month started offering a
fourth shot, or a second booster, to the most vulnerable and high-risk groups.
প্রধান সম্পাদকঃ সৈয়দ বোরহান কবীর
ক্রিয়েটিভ মিডিয়া লিমিটেডের অঙ্গ প্রতিষ্ঠান
বার্তা এবং বাণিজ্যিক কার্যালয়ঃ ২/৩ , ব্লক - ডি , লালমাটিয়া , ঢাকা -১২০৭
নিবন্ধিত ঠিকানাঃ বাড়ি# ৪৩ (লেভেল-৫) , রোড#১৬ নতুন (পুরাতন ২৭) , ধানমন্ডি , ঢাকা- ১২০৯
ফোনঃ +৮৮-০২৯১২৩৬৭৭